has for its cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.
The therapy is indicated to treat diffuse LBCL (DLBCL) primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) and follicular lymphoma grade 3B (FL3B) in adult patients whose disease relapsed within 12 months of completion of first-line chemoimmunotherapy, or who were refractory to it.
It is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain that improves CAR T cells鈥� expansion and persistence.
The regulatory approval covers all EU member states.
Bristol Myers Squibb senior vice-president and cell therapy development head Anne Kerber stated: 鈥淲ith Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit.
鈥淭his marks the approval of our third indication in Europe for our CAR T cell therapy portfolio, underscoring our continued drive to deliver the promise of cell therapy with curative potential for more patients.鈥�
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe EC’s approval is based on the data obtained from the pivotal Phase III TRANSFORM trial.
The multicentre, randomised, global, pivotal trial assessed Breyanzi in relapsed or refractory LBCL patients against the existing standard of care.
Breyanzi showed statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS), as well as the important secondary endpoints of progression-free survival (PFS) and complete responses (CR) compared to standard therapy.
In December 2022, as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by听Cytiva.
Editorial听content is independently produced and follows the听听of journalistic integrity. Topic sponsors are not involved in the creation of听editorial听content.
